ovi 'Breakthrough' COVID-19 Tests Are Currently Cheap, Fast--and Not Very Accurate By www.scientificamerican.com Published On :: Thu, 07 May 2020 10:45:00 GMT Antigen-based assays could be used in the home, but critics say their error rates are still an issue -- Read more on ScientificAmerican.com Full Article Health Public Health
ovi The COVID-19 Response Is Failing Communities of Color By blogs.scientificamerican.com Published On :: Thu, 07 May 2020 11:00:00 GMT To build trust with traditionally underserved groups, health officials need to craft their messaging in a much more culturally sensitive way -- Read more on ScientificAmerican.com Full Article Health Behavior & Society
ovi Scientist Mothers Face Extra Challenges in the Face of COVID-19 By blogs.scientificamerican.com Published On :: Thu, 07 May 2020 13:00:00 GMT The pandemic is amplifying nearly every disadvantage that women in STEM already face. But institutions and the scientific community can help -- Read more on ScientificAmerican.com Full Article The Sciences Policy & Ethics
ovi Cleaner Air Courtesy of Coronavirus Provides Window into a Car-Free Future By www.scientificamerican.com Published On :: Thu, 07 May 2020 15:30:00 GMT With cars off the roads, scientists can study how smog and other types of pollution change -- Read more on ScientificAmerican.com Full Article Sustainability Climate Environment Automotive
ovi Rabbit Virus Could Provide Gene Therapy By www.scientificamerican.com Published On :: Fri, 08 May 2020 15:00:00 GMT Originally published in February 1967 -- Read more on ScientificAmerican.com Full Article Medical & Biotech The Sciences Biology
ovi ACRO Members Heed the UK Government’s Call for Volunteers in Response to the COVID-19 Pandemic By www.acrohealth.org Published On :: Wed, 06 May 2020 19:08:12 +0000 May 6, 2020 – (Washington, DC) – In an effort to fight the global COVID-19 pandemic, over 150 employees from clinical research... Full Article News Press Releases
ovi Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments By www.news.bayer.com Published On :: Tue, 21 Apr 2020 12:30:00 GMT Investigation of combination therapies including Bayer’s chloroquine and interferon beta-1b to foster much needed solutions for patients in fight against coronavirus pandemic / Bayer Canada to make CAD 1.5 million (approximately 1 million euros) financial commitment and to supply products in support of the research / Plans to include more than 60 contributing research locations involving 6.000 patients Full Article
ovi Bayer: Good start to 2020 – activities marked by COVID-19 By www.news.bayer.com Published On :: Mon, 27 Apr 2020 05:30:00 GMT Employee safety and business continuity are top priorities / Wide-ranging humanitarian and social engagement / Group sales increase by 6.0 percent (Fx & portfolio adj.) to 12.845 billion euros / EBITDA before special items up by 10.2 percent to 4.391 billion euros / All divisions report higher sales and earnings – strong demand at Consumer Health / Net income advances by 20.0 percent to 1.489 billion euros / Core earnings per share increase by 9.9 percent to 2.67 euros / Outlook for 2020: impact of COVID-19 not yet reliably quantifiable Full Article
ovi Methadone to be supplied without new prescription during Covid-19 crisis By www.theguardian.com Published On :: 2020-04-08T05:00:08Z Pharmacists will be allowed to give out medication to patients who have already been receiving itPharmacists are to be allowed to hand out a range of super-strength medicines, including the heroin substitute methadone, without prescription during the Covid-19 crisis, under emergency measures that official drug policy advisers have warned could trigger a spike in drug misuse.The Advisory Council for Misuse of Drugs (ACMD), which makes recommendations to the government on the control of dangerous drugs, was asked by the home secretary to consider the risks of lifting restrictions on certain substances controlled under the Misuse of Drugs Act. Continue reading... Full Article Drugs policy UK news Pharmaceuticals industry Drugs Coronavirus outbreak Politics Science Society
ovi US stays away as world leaders agree action on Covid-19 vaccine By www.theguardian.com Published On :: 2020-04-24T16:55:50Z Video meeting seen as global endorsement of WHO and sign of Trump’s isolation on world stageCoronavirus – latest updatesSee all our coronavirus coverageGlobal leaders have pledged to accelerate cooperation on a coronavirus vaccine and to share research, treatment and medicines across the globe. But the United States did not take part in the World Health Organization initiative, in a sign of Donald Trump’s increasing isolation on the global stage.The cooperation pledge, made at a virtual meeting, was designed to show that wealthy countries will not keep the results of research from developing countries. Related: The hunt for a coronavirus vaccine – a perilous and uncertain path Related: ‘Please don’t inject bleach’: Trump’s wild coronavirus claims prompt disbelief Provide access to new treatments, technologies and vaccines across the world.Commit to an unprecedented level of international partnership on research and coordinate efforts to tackle the pandemic and reduce infections.Reach collective decisions on responding to the pandemic, recognising that the virus’s spread in one country can affect all countries.Learn from experience and adapt the global response.Be accountable, to the most vulnerable communities and the whole world. Continue reading... Full Article Coronavirus outbreak World Health Organization United Nations Emmanuel Macron Angela Merkel Donald Trump Health Infectious diseases Medical research Microbiology US news World news US foreign policy G20 G7 Bill Gates China UK news Pharmaceuticals industry Science
ovi Covid-19 could mark a deadly turn in Ghana's fight against fake drugs By www.theguardian.com Published On :: 2020-04-30T08:00:15Z With substandard medicines already in wide circulation, fears are growing that coronavirus could create a lethal ‘parallel crisis’When Joana Opoku-Darko’s daughter Anna was 18 months old, she came down with malaria, a disease common in Ghana and especially deadly for children.She bought medication from a pharmacy in Ghana’s capital, Accra; when Anna’s fever didn’t subside she took her to a hospital, where they ran some tests.The current focus on curbing Covid-19 spread means there is less focus on routine market surveillance Related: Fight the fakes: how to beat the $200bn medicine counterfeiters | Helen Lock Continue reading... Full Article Global health Ghana Global development Health Pharmaceuticals industry Healthcare industry Society World news Africa
ovi Promising drug against Covid-19 unlikely to be available in UK soon By www.theguardian.com Published On :: 2020-04-30T16:50:55Z Trial of remdesivir shows fewer deaths and shorter hospital staysCoronavirus – latest updatesSee all our coronavirus coverageThe first drug against Covid-19 to show promise in trials, reducing the time seriously ill people take to recover in hospital, is unlikely to be available widely in the UK soon, it has emerged.Forty-six people in the UK have received remdesivir as part of the European arm of an international trial. Researchers would like to have given the drug to more patients but did not have the supplies. Related: Coronavirus: what do scientists know about Covid-19 so far? Continue reading... Full Article Medical research Health Pharmaceuticals industry Coronavirus outbreak Science UK news Society
ovi AstraZeneca partners with Oxford University to produce Covid-19 vaccine By www.theguardian.com Published On :: 2020-04-30T16:50:57Z Drugmaker will manufacture and distribute vaccine if human trials are successfulCoronavirus – latest updatesSee all our coronavirus coverageAstraZeneca, the Cambridge-based pharmaceutical group, is teaming up with Oxford University to manufacture and distribute a coronavirus vaccine if clinical trials currently under way show it is effective.News of the partnership boosted AstraZeneca’s share price, helping it to become Britain’s most valuable company by market capitalisation. Related: The hunt for a coronavirus vaccine – a perilous and uncertain path Continue reading... Full Article AstraZeneca Pharmaceuticals industry Vaccines and immunisation Coronavirus outbreak UK news Business University of Oxford Research Medical research
ovi Leading COVID-19 hope remdesivir fails to provide clinical benefit in first randomised trial By www.pharmafile.com Published On :: Fri, 24 Apr 2020 11:29:51 +0000 Gilead’s remdesivir, which has been hailed as one of the few truly promising treatments for COVID-19 at this early stage of the ongoing pandemic, has failed in its first randomised clinical trial, leaked data has revealed. Full Article coronavirus COVID-19 Gilead pharma remdesivir Research and Development Medical Communications
ovi FDA urges close monitoring of COVID-19 patients treated with hydroxychloroquine By www.pharmafile.com Published On :: Mon, 27 Apr 2020 08:37:56 +0000 The FDA has released a safety communication reiterating the need for doctors to closely monitor COVID-19 patients who are treated with either hydroxychloroquine or chloroquine. Full Article chloroquine coronavirus COVID-19 FDA hydroxychloroquine Sales and Marketing
ovi Italy to relax COVID-19 lockdown in early May By www.pharmafile.com Published On :: Mon, 27 Apr 2020 11:35:23 +0000 Italy has outlined its plans to ease the lockdown restrictions that were implemented across the country 7 weeks ago to combat the COVID-19 coronavirus pandemic. Full Article coronavirus COVID-19 COVID-19 coronavirus Italy Sales and Marketing
ovi 12 British children hospitalised with rare condition linked to COVID-19 By www.pharmafile.com Published On :: Tue, 28 Apr 2020 09:25:30 +0000 12 children have fallen ill across the UK with a new and potentially fatal combination of symptoms linked to COVID-19. Full Article coronavirus COVID-19 NHS NHS UK Manufacturing and Production
ovi South Korean researchers start testing pancreatitis drug in COVID-19 patients By www.pharmafile.com Published On :: Tue, 28 Apr 2020 10:19:05 +0000 The South Korean Ministry of Food and Drug Safety have approved a local trial to evaluate nafamostat’s effectiveness in COVID-19 patients. Full Article coronavirus COVID-19 Pancreas Pancreatitis Manufacturing and Production
ovi Nearly half of Americans believe COVID-19 was created in a lab, according to a new survey By www.pharmafile.com Published On :: Tue, 28 Apr 2020 11:31:39 +0000 Almost half of Americans believe that the coronavirus was created in a lab, according to an April survey of 6,300 people. Full Article coronavirus COVID-19 survey Manufacturing and Production
ovi Pharmafile.com's weekly COVID-19 news round-up By www.pharmafile.com Published On :: Wed, 29 Apr 2020 10:54:33 +0000 Hydroxychloroquine continues to feature in coronavirus news. Rick Bright, the Director of BARDA, alleges he was pushed out of his position due to his pushback to the administration focusing on the use of hydroxychloroquine in COVID-19 patients. This came after the National Institutes of Health said coronavirus patients should not take the drug due to potential “toxicities.” Full Article BARDA coronavirus COVID-19 hydroxychloroquine Research and Development
ovi Arizona GOP lawmakers and AAPS say hydroxychloroquine has 90% chance of helping COVID-19 patients, but data is not based on clinical trials By www.pharmafile.com Published On :: Wed, 29 Apr 2020 11:58:38 +0000 The Association of American Physicians and Surgeons (AAPS) wrote a letter to Republican Arizona Governor Doug Ducey urging the wider use of hydroxychloroquine, based on data they have collected. Full Article chloroquine hydroxychloroquine Research and Development
ovi Men most likely to exhibit the worst COVID-19 symptoms, according to a new study By www.pharmafile.com Published On :: Thu, 30 Apr 2020 09:24:33 +0000 Research into coronavirus cases in Shenzhen, China found that men were 2.5 times as likely to exhibit severe symptoms. Full Article coronavirus COVID-19 Business Services
ovi Two studies reveal "positive" data for Gilead's remdesivir in hospitalised COVID-19 patients By www.pharmafile.com Published On :: Thu, 30 Apr 2020 10:12:25 +0000 The first findings of two new studies have been revealed detailing the efficacy of Gilead’s antiviral therapy remdesivir in the treatment of patients hospitalised with COVID-19. Full Article coronavirus COVID-19 Gilead remdesivir Research and Development
ovi COVID-19 pandemic likely to last two years, study says By www.pharmafile.com Published On :: Fri, 01 May 2020 10:53:09 +0000 The coronavirus pandemic is likely to last as long as two years and will not be properly controlled until two-thirds of the world’s populations have become immune. Full Article coronavirus COVID-19 pandemic Medical Communications
ovi Mike Pompeo says there is evidence COVID-19 was made in a lab, despite US intelligence saying it occurred naturally By www.pharmafile.com Published On :: Mon, 04 May 2020 09:20:26 +0000 US Secretary of State Mike Pompeo claimed that there is evidence the COVID-19 coronavirus was created in a lab, despite US intelligence officials stating it probably occurred naturally. Full Article coronavirus COVID-19 lab pandemic Wuhan Institute of virology Sales and Marketing
ovi UK testing experimental treatment for use in COVID-19 patients By www.pharmafile.com Published On :: Mon, 04 May 2020 10:06:21 +0000 British scientists are testing an experimental drug to help some of society’s most vulnerable fight off the COVID-19 coronavirus. Full Article coronavirus coronavirus treatment COVID-19 Sales and Marketing
ovi FDA approves emergency use of Gilead's remdesivir for hospitalised COVID-19 patients By www.pharmafile.com Published On :: Mon, 04 May 2020 11:31:55 +0000 Gilead’s antiviral therapy remdesivir has shown tentatively promising efficacy in the race to find an effective treatment for COVID-19, one of the only therapies to do so at this early stage of the pandemic. Now, the FDA has invoked its Emergency Use Authorization powers to approve the drug for the treatment of patients hospitalised with the novel coronavirus. Full Article coronavirus COVID-19 FDA Gilead remdesivir Sales and Marketing
ovi MHRA launches new pharmacovigilance reporting platform for COVID-19 treatments By www.pharmafile.com Published On :: Tue, 05 May 2020 10:27:13 +0000 A new online reporting site has been launched by the Medicines and Healthcare products Regulatory Agency’s (MHRA) to track potential side-effects arising from the use of any therapies used to treat COVID-19, in a bid to build a knowledge base around safe treatment of the pandemic disease. Full Article coronavirus COVID-19 MHRA pharma Research and Development UK Manufacturing and Production
ovi First French case of COVID-19 occurred in December, a month earlier than previously thought By www.pharmafile.com Published On :: Tue, 05 May 2020 11:46:00 +0000 A French patient who suffered from pneumonia in December actually had COVID-19, it has been revealed. Full Article coronavirus COVID-19 Manufacturing and Production
ovi Ousted chief of BARDA says Trump administration ignored COVID-19 warnings By www.pharmafile.com Published On :: Wed, 06 May 2020 09:33:46 +0000 Ousted Director of the Biomedical Advanced Research and Development Authority (BARDA), Dr Rick Bright, alleges the Trump administration ignored warnings about the severity of the coronavirus. Full Article BARDA chloroquine coronavirus COVID-19 hydroxychloroquine Research and Development
ovi Pharmafile.com's weekly COVID-19 news round-up By www.pharmafile.com Published On :: Wed, 06 May 2020 10:17:43 +0000 Vaccines and treatments for COVID-19 continue to dominate the news, as two studies reveal "positive" data for Gilead's remdesivir in hospitalised coronavirus patients while Lonza and Moderna have entered an agreement to mass produce a vaccine. Full Article coronavirus COVID-19 Research and Development
ovi Scientists in the UK and US identify hundreds of mutations in the COVID-19 virus By www.pharmafile.com Published On :: Thu, 07 May 2020 09:42:57 +0000 Two studies from the UK and US have identified hundreds of mutations in COVID-19, which could cause problems for the development of a vaccine. Full Article coronavirus COVID-19 Protein virus Business Services
ovi UK becomes first European country to pass 30,000 deaths from COVID-19 By www.pharmafile.com Published On :: Thu, 07 May 2020 10:31:27 +0000 Britain has become the first European nation to pass 30,000 deaths from the coronavirus, putting it only behind the US as the worst hit country in the world in terms of fatalities. Full Article coronavirus COVID-19 Business Services
ovi Black people are four times more likely to die from COVID-19 than white in England and Wales, ONS report shows By www.pharmafile.com Published On :: Thu, 07 May 2020 11:53:35 +0000 A recent report from the Office of National Statistics (ONS) has shown that black people in Britain are four times more likely to die from the COVID-19 coronavirus than white Britons. Full Article coronavirus COVID-19 Business Services
ovi EMA starts rolling review of Gilead’s COVID-19 hope remdesivir By www.pmlive.com Published On :: Fri, 01 May 2020 13:01:24 +0100 New crop of data suggests drug can speed recovery from COVID-19 Full Article
ovi Amgen adds Otezla to the COVID-19 candidate list By www.pmlive.com Published On :: Mon, 04 May 2020 12:18:21 +0100 Psoriasis therapy may be a potential treatment for COVID-19 Full Article
ovi Roche’s COVID-19 antibody test approved for emergency use in the US By www.pmlive.com Published On :: Mon, 04 May 2020 12:25:11 +0100 Ramps up capacity for testing across the country Full Article
ovi Alnylam and Vir plan gene-silencing attack on COVID-19 virus By www.pmlive.com Published On :: Tue, 05 May 2020 12:59:41 +0100 Drug could be ready for clinical trials before the end of the year Full Article
ovi World leaders donate to COVID-19 vaccine funding drive By www.pmlive.com Published On :: Tue, 05 May 2020 13:08:40 +0100 Experts says $20bn needed to vaccinate global population Full Article
ovi Regeneron says antibody for COVID-19 could be ready this year By www.pmlive.com Published On :: Thu, 07 May 2020 15:59:05 +0100 Two antibody cocktails for COVID-19 could be available as early as this autumn Full Article
ovi COVID-19 Core Formula By www.flickr.com Published On :: Fri, 08 May 2020 11:07:04 -0700 The U.S. Food and Drug Administration posted a photo: This product is promoted with unapproved claims to prevent, treat, mitigate, or cure COVID-19. FDA warns consumers to avoid unproven and potentially unsafe products. See the Warning Letter for more information: www.fda.gov/inspections-compliance-enforcement-and-crimin... More information is available at www.fda.gov/consumers/health-fraud-scams/fraudulent-coron... Photo by FDA's Office of Regulatory Affairs, Health Fraud Branch This photo is free of all copyright restrictions and available for use and redistribution without permission. Credit to FDA's Office of Regulatory Affairs, Health Fraud Branch is appreciated but not required. Full Article
ovi Oxford COVID-19 vaccine programme opens for clinical trial recruitment By www.pharmanews.eu Published On :: Thu, 23 Apr 2020 10:00:00 +0200 University of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won’t be ready for some weeks still. Full Article Featured Research Research & Development
ovi AstraZeneca and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients By www.pharmanews.eu Published On :: Fri, 24 Apr 2020 10:00:00 +0200 AstraZeneca and Saint Luke's Mid America Heart Institute have initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a treatment in patients hospitalised with COVID-19 who are at risk of developing serious complications, such as organ failure. Full Article Featured AstraZeneca Business
ovi Key nose cells identified as likely COVID-19 virus entry points By www.pharmanews.eu Published On :: Mon, 27 Apr 2020 10:00:00 +0200 Two specific cell types in the nose have been identified as likely initial infection points for COVID-19 coronavirus. Scientists discovered that goblet and ciliated cells in the nose have high levels of the entry proteins that the COVID-19 virus uses to get into our cells. The identification of these cells by researchers from the Full Article Featured Research Research & Development
ovi Loss of smell associated with milder clinical course in COVID-19 By www.pharmanews.eu Published On :: Tue, 28 Apr 2020 10:00:00 +0200 Following an earlier study that validated the loss of smell and taste as indicators of SARS-CoV-2 infection, researchers at UC San Diego Health report in newly published findings that olfactory impairment suggests the resulting COVID-19 disease is more likely to be mild to moderate, a potential early indicator that could help health care providers determine which patients may require hospitalization. Full Article Featured Research Research & Development
ovi Novartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia By www.pharmanews.eu Published On :: Wed, 29 Apr 2020 10:00:00 +0200 Novartis announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the efficacy of utilizing canakinumab, an interleukin (IL)-1β blocker, to treat a type of severe immune overreaction called cytokine release syndrome (CRS) in people with COVID-19 pneumonia. Full Article Featured Novartis Business
ovi AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine By www.pharmanews.eu Published On :: Thu, 30 Apr 2020 10:00:00 +0200 AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2. The collaboration aims to bring to patients the potential vaccine known as ChAdOx1 nCoV-19, being developed by the Jenner Institute and Oxford Vaccine Group, at the University of Oxford. Full Article Featured AstraZeneca Business
ovi Antibodies from llamas could help in fight against COVID-19 By www.pharmanews.eu Published On :: Fri, 01 May 2020 10:00:00 +0200 The hunt for an effective treatment for COVID-19 has led one team of researchers to find an improbable ally for their work: a llama named Winter. The team - from The University of Texas at Austin, the National Institutes of Health and Ghent University in Belgium - reports their findings about a potential avenue for a coronavirus treatment involving llamas on May 5 in the journal Cell. Full Article Featured Research Research & Development
ovi Researchers identify four possible treatments for COVID-19 By www.pharmanews.eu Published On :: Mon, 04 May 2020 10:00:00 +0200 While COVID-19 has infected millions of people worldwide and killed hundreds of thousands, there is currently no vaccine. In response, researchers have been evaluating the effectiveness of various antiviral drugs as possible COVID-19 treatments. Full Article Featured Research Research & Development
ovi Study reveals most critically ill patients with COVID-19 survive with standard treatment By www.pharmanews.eu Published On :: Wed, 06 May 2020 10:00:00 +0200 Clinicians from two hospitals in Boston report that the majority of even the sickest patients with COVID-19 - those who require ventilators in intensive care units - get better when they receive existing guideline-supported treatment for respiratory failure. The clinicians, who are from Massachusetts General Hospital (MGH) and Beth Israel Deaconess Medical Center, published their findings in the American Journal of Respiratory and Critical Care Medicine. Full Article Featured Research Research & Development